APOL1 and nephropathy progression in populations of African ancestry.

[1]  M. Rocco,et al.  JC polyoma virus interacts with APOL1 in African Americans with non-diabetic nephropathy , 2013, Kidney international.

[2]  M. Simmonds,et al.  Donor ABCB1 variant associates with increased risk for kidney allograft failure. , 2012, Journal of the American Society of Nephrology : JASN.

[3]  C. Rotimi,et al.  Multiple Loci Associated with Renal Function in African Americans , 2012, PloS one.

[4]  C. Rotimi,et al.  Variation in APOL1 Contributes to Ancestry-Level Differences in HDLc-Kidney Function Association , 2012, International journal of nephrology.

[5]  C. Wyatt,et al.  APOL1 variants in HIV-associated nephropathy: just one piece of the puzzle. , 2012, Kidney international.

[6]  G. Genovese,et al.  The APOL1 Genotype of African American Kidney Transplant Recipients Does Not Impact 5‐Year Allograft Survival , 2012, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[7]  B. Astor,et al.  Apolipoprotein L1 gene variants associate with hypertension-attributed nephropathy and the rate of kidney function decline in African Americans , 2012, Kidney international.

[8]  M. Rocco,et al.  Association of APOL1 variants with mild kidney disease in first-degree relatives of African American patients with non-diabetic end stage renal disease , 2012, Kidney international.

[9]  C. Langefeld,et al.  Polymorphisms in MYH9 are associated with diabetic nephropathy in European Americans. , 2012, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[10]  S. Rosset,et al.  APOL1 allelic variants are associated with lower age of dialysis initiation and thereby increased dialysis vintage in African and Hispanic Americans with non-diabetic end-stage kidney disease. , 2012, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[11]  C. Langefeld,et al.  The new era of APOL1-associated glomerulosclerosis. , 2012, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[12]  C. Winkler,et al.  HIV-associated nephropathy patients with and without apolipoprotein L1 gene variants have similar clinical and pathologic characteristics , 2012, Kidney international.

[13]  G. Remuzzi,et al.  Proteinuria should be used as a surrogate in CKD , 2012, Nature Reviews Nephrology.

[14]  P. Kimmel,et al.  Genetic association and gene-gene interaction analyses in African American dialysis patients with nondiabetic nephropathy. , 2012, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[15]  D. Fine,et al.  APOL1 risk variants predict histopathology and progression to ESRD in HIV-related kidney disease. , 2012, Journal of the American Society of Nephrology : JASN.

[16]  B. Freedman,et al.  Target Organ Damage in African American Hypertension: Role of APOL1 , 2012, Current Hypertension Reports.

[17]  P. Gaffney,et al.  Role of MYH9 and APOL1 in African and non-African populations with lupus nephritis , 2011, Genes and Immunity.

[18]  C. Langefeld,et al.  Sickle cell trait is not independently associated with susceptibility to end-stage renal disease in African Americans. , 2011, Kidney international.

[19]  A. Ashley-Koch,et al.  MYH9 and APOL1 are both associated with sickle cell disease nephropathy , 2011, British Journal of Haematology.

[20]  M. Rocco,et al.  Apolipoprotein L1 nephropathy risk variants associate with HDL subfraction concentration in African Americans. , 2011, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[21]  N. Powe,et al.  Genetic variation in APOL1 associates with younger age at hemodialysis initiation. , 2011, Journal of the American Society of Nephrology : JASN.

[22]  G. Genovese,et al.  Population-based risk assessment of APOL1 on renal disease. , 2011, Journal of the American Society of Nephrology : JASN.

[23]  J. O'Toole,et al.  APOL1 localization in normal kidney and nondiabetic kidney disease. , 2011, Journal of the American Society of Nephrology : JASN.

[24]  C. Young,et al.  African American living-kidney donors should be screened for APOL1 risk alleles. , 2011, Transplantation.

[25]  Giulio Genovese,et al.  APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy. , 2011, Journal of the American Society of Nephrology : JASN.

[26]  S. Rosset,et al.  Absence of APOL1 Risk Variants Protects against HIV-Associated Nephropathy in the Ethiopian Population , 2011, American Journal of Nephrology.

[27]  J. Lv,et al.  Polymorphisms in the nonmuscle myosin heavy chain 9 gene (MYH9) are associated with the progression of IgA nephropathy in Chinese. , 2011, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[28]  A. Köttgen,et al.  The MYH9/APOL1 region and chronic kidney disease in European-Americans. , 2011, Human molecular genetics.

[29]  M. Rocco,et al.  The APOL1 Gene and Allograft Survival after Kidney Transplantation , 2011, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[30]  C. Young,et al.  Living Donor Nephrectomy: Understanding Long‐Term Risk in Minority Populations , 2010, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[31]  C. Winkler,et al.  The apolipoprotein L1 (APOL1) gene and nondiabetic nephropathy in African Americans. , 2010, Journal of the American Society of Nephrology : JASN.

[32]  M. Schnitzler,et al.  Racial variation in medical outcomes among living kidney donors. , 2010, The New England journal of medicine.

[33]  C. Winkler,et al.  Association of Trypanolytic ApoL1 Variants with Kidney Disease in African Americans , 2010, Science.

[34]  S. Rosset,et al.  Missense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 gene , 2010, Human Genetics.

[35]  C. Winkler,et al.  The Non-Muscle Myosin Heavy Chain 9 Gene (MYH9) Is Not Associated with Lupus Nephritis in African Americans , 2010, American Journal of Nephrology.

[36]  B. Freedman,et al.  The spectrum of MYH9-associated nephropathy. , 2010, Clinical journal of the American Society of Nephrology : CJASN.

[37]  M. Simmonds,et al.  Association of caveolin-1 gene polymorphism with kidney transplant fibrosis and allograft failure. , 2010, JAMA.

[38]  L. Appel,et al.  Compelling evidence for public health action to reduce salt intake. , 2010, The New England journal of medicine.

[39]  Thomas Meitinger,et al.  Genome-wide linkage analysis of serum creatinine in three isolated European populations. , 2009, Kidney international.

[40]  Yongmei Liu,et al.  Polymorphisms in the non-muscle myosin heavy chain 9 gene (MYH9) are strongly associated with end-stage renal disease historically attributed to hypertension in African Americans. , 2009, Kidney international.

[41]  D. Reich,et al.  MYH9 is associated with nondiabetic end-stage renal disease in African Americans , 2008, Nature Genetics.

[42]  D. Vlahov,et al.  MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis , 2008, Nature Genetics.

[43]  Keith C. Norris,et al.  Long-term effects of renin-angiotensin system-blocking therapy and a low blood pressure goal on progression of hypertensive chronic kidney disease in African Americans. , 2008, Archives of internal medicine.

[44]  V. Howard,et al.  Racial differences in the prevalence of chronic kidney disease among participants in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) Cohort Study. , 2006, Journal of the American Society of Nephrology : JASN.

[45]  A. Bakkaloğlu,et al.  Patients with mutations in NPHS2 (podocin) do not respond to standard steroid treatment of nephrotic syndrome. , 2004, Journal of the American Society of Nephrology : JASN.

[46]  Tom Greene,et al.  Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. , 2002, JAMA.

[47]  L. Agodoa,et al.  Human immunodeficiency virus/acquired immunodeficiency syndrome-associated nephropathy at end-stage renal disease in the United States: patient characteristics and survival in the pre highly active antiretroviral therapy era. , 2001, Journal of nephrology.

[48]  S. Iyengar,et al.  Inaccuracy of clinical phenotyping parameters for hypertensive nephrosclerosis. , 2000, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[49]  J. Bourgoignie.  Acquired immunodeficiency syndrome (AIDS) — Related renal disease , 1989, Klinische Wochenschrift.

[50]  E A Friedman,et al.  Associated focal and segmental glomerulosclerosis in the acquired immunodeficiency syndrome. , 1984, The New England journal of medicine.

[51]  S. Rich,et al.  Genetic Basis of Kidney Disease , 2012 .

[52]  Donald W. Bowden,et al.  Association of Trypanolytic ApoL 1 Variants with Kidney Disease in African Americans , 2010 .

[53]  D. Behar,et al.  Absence of HIV-associated nephropathy in Ethiopians. , 2006, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[54]  J. Breyer,et al.  Accuracy of the diagnosis of hypertensive nephrosclerosis in African Americans: a report from the African American Study of Kidney Disease (AASK) Trial. AASK Pilot Study Investigators. , 1997, Kidney international.

[55]  B. Brenner,et al.  Brenner & Rector's the Kidney , 1996 .